Pay in 4 interest-free payments of $6.82 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
inked a potential $938 million licensing deal for APL-18881 (HEC-88473), Sunshines dual fibroblast growth factor 21 (FGF21)/glucagon-like peptide-1 (GLP-1) receptor agonist currently in a phase II study for type 2 diabetes
Women should consult their healthcare provider about appropriate timing for discontinuation, as the medication has a half-life of approximately 5 days with elimination occurring over several weeks
doi: 10.1002/biof.2121 207
Consequently, food and beverage companies continue to avoid high-capex solutions unless fibers function as drop-in replacements
US$ 25.44
US$ 26.59
US$ 24.95
US$ 22.87
US$ 28.98
